AI assistant
Adaptimmune Therapeutics PLC — Director's Dealing 2020
Jan 16, 2020
34721_dirs_2020-01-15_5b1163aa-2903-4c16-90b4-dc426a8be0f1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2020-01-13
Reporting Person: Noble James (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-01-13 | American Depositary Shares | S | 100000 | $4.00 | Disposed | 0 | Direct |
| 2020-01-13 | American Depositary Shares | S | 200000 | $5.00 | Disposed | 0 | Direct |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2019.
F2: These ADSs were sold in multiple transactions at a price of $4.00. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at this price in this footnote.
F3: These ADSs were sold in multiple transactions at a price of $5.00. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at this price in this footnote.